Protocol Ledger

NCT05786716 · Phase II/III · RECRUITING

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

Interventional Phase II/III clinical trial protocol NCT05786716 sponsored by Cancer Research UK in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-07 Enrollment: 30 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05786716
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)30 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05786716
Protocol FieldVerified Registry Value
NCT IdentifierNCT05786716
Consolidated Lead SponsorCancer Research UK
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment30 participants (ESTIMATED)
Registered Start Date2023-03-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05786716
Hospital Research SiteLocationSite Profile
Addenbrooke's HospitalCambridge, United KingdomOpen Hospital Dossier ->
Western General HospitalEdinburgh, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI